Mr. Tony O'Brien:

Given the right regulatory environment, we will certainly be able to get better value. It is important to stress the reason drugs companies do this is for them market share is a tradeable commodity and goes to the value of their brands, stocks and shares. That is the incentive for them. The reason they are able to do it is they can sustain a higher list price within which they can make these swaps. Once market conditions do not facilitate the maintenance of the higher price, they will not be able to do it anymore.